CRISPR therapy shows promise in early trial for fatal muscle disease
NCT ID NCT06594094
First seen Jun 27, 2026 · Last updated Aug 04, 2026 · Updated 2 times
Summary
This early-phase study tested a new gene editing treatment called HG302 in 4 boys with Duchenne muscular dystrophy (DMD), a severe muscle-wasting disease. The therapy uses CRISPR technology to fix the genetic error and help muscles produce dystrophin, a protein essential for muscle strength. The main goal was to check safety, but researchers also looked for signs that the treatment restored dystrophin and improved muscle function.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Early phase 1
The earliest testing in people: a first look at safety, in a very small group.
- Participants
-
4 people
The number who actually took part.
- Started
-
Nov 2024
- Expected to finish
-
Jun 2027
An estimate. End dates often move.
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
4 to 8 years
- Sex
-
Male participants only
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Males ≥ 4 and ≤8 years at the time of signing informed consent, with clinical diagnosis of DMD; * DMD gene mutation types are deletions in exons 52, 52-61, or 52-63; * Able to walk at least 10 meters independently; * Willing to cooperate with muscle biopsy test; * Acceptable hematology, clinical chemistry, and urine laboratory parameters. Exclusion Criteria: * Presence of active infection; * Presence of DMD-associated cardiomyopathy manifestations; * Respiratory insufficiency requiring invasive or non-invasive ventilation; * Serious infections such as pneumonia, pyelonephritis, or meningitis within 4 weeks prior to receiving trial drug infusion; * Prior central nervous system surgery within 6 months before enrolment; * Use of any investigational drug, or exon-skipping drug (whether investigational or not) 6 months prior to Screening; * Previous treatment with any gene therapy or cell therapy (e.g., stem cell transplantation); * Any other conditions that would not allow the potential subject to complete follow-up examinations during the study and would, in the opinion of the investigator, make the potential subject unsuitable for the study.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Duchenne muscular dystrophin (DMD) are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Shanghai Children s Medical Center Affiliated to Shanghai Jiao Tong University School of Medical
Shanghai, Shanghai Municipality, China